Benzinga | Jun 17, 2021 09:17AM EDT

HC Wainwright & Co. Downgrades Kindred Biosciences to Neutral, Raises Price Target to $9.25

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Kindred Biosciences (NASDAQ:KIN) from Buy to Neutral and raises the price target from $9 to $9.25.HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Kindred Biosciences (NASDAQ:KIN) from Buy to Neutral and raises the price target from $9 to $9.25.